The global renal biomarkers market size accounted for USD 1.62 billion in 2024, grew to USD 1.76 billion in 2025 and is predicted to be worth around USD 3.57 billion by 2034, registering a solid CAGR of 8.21% between 2024 and 2034. The North America renal biomarkers market size is evaluated at USD 780 million in 2024 and is estimated to grow at CAGR of 8.29% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Renal Biomarkers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Renal Biomarkers Market Revenue and Volume, by Biomarker, 2024-2034
8.1.1 Functional Biomarker
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Up-regulated Protein
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Other Biomarker
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Renal Biomarkers Market Revenue and Volume, by Diagnostic Technique, 2024-2034
9.1.1. Enzyme-linked Immunosorbent Assay
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Colorimetric Assay
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Particle-enhanced Turbidimetric Immunoassay (PETIA)
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Chemiluminescent Enzyme Immunoassay (CLIA)
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Liquid Chromatography Mass
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
9.1.6. Spectrometry (LC-MS)
9.1.6.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Renal Biomarkers Market Revenue and Volume, by End-user, 2024-2034
10.1.1. Hospital
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Diagnostic Laboratory
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Other
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Biomarker (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Beckman Coulter Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. BioMérieux
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. BioPorto Diagnostics AS
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BIO-RAD LABORATORIES INC.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. F. HOFFMANN-LA ROCHE LTD.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Randox Laboratories Ltd
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. SEKISUI MEDICAL CO., LTD.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Siemens Healthineers AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sphingotec GmbH
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample